Expansion and characterization of relevant simian immunodeficiency virus (SIV) stocks for use in drug assays or repeat, low-dose challenge studies in rhesus macaques
Ended Awarded Last action
- Contract number
- 75N93018F00012
- Awardee
-
Advanced Bioscience Laboratories, Inc. UEI MK4QC9EKZXG8
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $603,935
Award facts
- Opportunity
-
- NIAIDDAIDSNIHAI2015029 Solicitation number
- Comprehensive Resources for HIV Microbicides and Biomedical Prevention Award Notice · Posted Jun 24, 2015
- Contract value 98% obligated
-
- $603,935.45 Current, with exercised options
- $615,313.45 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Rockville, MD 20850, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | $1,473 | |
| Funding Only Action | $83,598 | |
| Change Order | $0 | |
| Other Administrative Action | $0 | |
| Funding Only Action | $158,927 | |
| Other Administrative Action | $0 | |
| Original award | $359,937 |
About this award
This is a federal contract awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases to Advanced Bioscience Laboratories, Inc. (ABL) on July 12, 2018. The $615,313.45 cost-plus-fixed-fee contract is for the expansion and characterization of relevant simian immunodeficiency virus (SIV) stocks for use in drug assays or repeat, low-dose challenge studies in rhesus macaques. This contract falls under the NIH's "HIV Microbicides and Biomedical Prevention 2016-2021" master indefinite-delivery/indefinite-quantity (IDIQ) contract vehicle. ABL, a foreign-owned, for-profit organization that manufactures goods, has been awarded over $35 million in federal contracts to support preclinical and clinical product development for the NIH and HHS. This contract does not have a set-aside designation.
Quick answers
Who was awarded contract 75N93018F00012?
75N93018F00012 was awarded to Advanced Bioscience Laboratories, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on July 12, 2018.
How much is contract 75N93018F00012 worth?
The government has obligated $603,935 on 75N93018F00012. Its potential value, with all options, is $615,313.
Is contract 75N93018F00012 an order under another contract?
Yes. 75N93018F00012 is a delivery order under HHSN272201600008I, an indefinite delivery contract, on HIV Microbicides and Biomedical Prevention 2016-2021.
Was contract 75N93018F00012 competed?
The extent of competition for 75N93018F00012 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award